The Monoclonal Antibodies Strike Back: New Data on Their Use in COVID-19

CCO Infectious Disease Podcast

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:

• Rationale for use of mAb
• Potential for resistance to mAb
• Single vs combination therapy with mAb
• Challenges in implementation of mAb as treatment or prevention
• Bamlanivimab
• Sotrovimab
• Casirivimab plus imdevimab

Link to full program, including downloadable slidesets: https://bit.ly/3zVTwYW

Presenters:

Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
Faculty Medicine Dentistry and Health Sciences
University of Melbourne and Royal Melbourne Hospital
Consultant Infectious Diseases Physician
Department of Infectious Diseases
Royal Melbourne Hospital and Alfred Hospital
Melbourne, Australia

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Sharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor.